


The burden of antimicrobial resistance (AMR) in Sudan

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **6,000 lives** have been lost each year since 1990 in Sudan due to AMR.
- In 2021, there were an estimated **3,940 UI (2,840-5,030)** deaths attributable to AMR and **14,600 UI (10,500-18,600)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **under 5** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Acinetobacter baumannii* resistant to carbapenems and *Streptococcus pneumoniae* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Sudan, a 10% reduction means to decrease the number of deaths associated with AMR to **14,500**, but currently the trend for this country could reach up to **17,100 UI [11,400-25,000]** AMR-associated deaths in 2030.

AMR in Sudan

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Sudan between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Sudan** in 2021, there were an estimated **3,940 UI (2,840-5,030)** deaths attributable to AMR and **14,600 UI (10,500-18,600)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Sudan has the 99th highest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

	Overall susceptible and resistant	Associated	Attributable
Burden rank	Streptococcus pneumoniae 3,230 UI (2,430-4,030) ↓	Streptococcus pneumoniae 2,430 UI (1,650-3,220) ↓	Acinetobacter baumannii 869 UI (680-1,060) ↓
	Staphylococcus aureus 2,780 UI (2,100-3,460) ↑	Klebsiella pneumoniae 2,160 UI (1,600-2,720) ↓	Klebsiella pneumoniae 590 UI (433-748) ↓
	Klebsiella pneumoniae 2,590 UI (1,950-3,230) ↓	Acinetobacter baumannii 2,160 UI (1,620-2,700) ↓	Staphylococcus aureus 587 UI (398-776) ↑
	Pseudomonas aeruginosa 2,180 UI (1,640-2,720) ↓	Staphylococcus aureus 2,030 UI (1,370-2,690) ↑	Streptococcus pneumoniae 577 UI (350-804) ↓
	Acinetobacter baumannii 2,160 UI (1,620-2,700) ↓	Escherichia coli 1,680 UI (1,260-2,090) ↓	Pseudomonas aeruginosa 419 UI (269-569) ↓
	Escherichia coli 1,860 UI (1,420-2,310) ↓	Pseudomonas aeruginosa 1,570 UI (1,110-2,040) ↓	Escherichia coli 388 UI (279-497) ↓
	Mycobacterium tuberculosis 1,330 UI (794-1,860) ↓	Enterobacter spp. 420 UI (312-528) ↓	Enterobacter spp. 126 UI (93-159) ↓
	Group B Streptococcus 660 UI (475-845) ↓	Group B Streptococcus 303 UI (192-414) ↓	Serratia spp. 80 UI (57-103) ↓
	Serratia spp. 522 UI (386-657) ↓	Serratia spp. 296 UI (212-380) ↓	Enterococcus faecalis 46 UI (26-66) ↑
	Haemophilus influenzae 508 UI (380-636) ↓	Proteus spp. 252 UI (176-329) ↑	Proteus spp. 41 UI (25-57) ↑

Annualized rate of change (1990-2021):
 <-3% (dark blue), -3% to -1.5% (medium blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (light orange), 3% to 5% (dark orange), >5.0% (red)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

	Associated	Attributable
Burden Rank	Acinetobacter baumannii 3GC 2,160 UI (1,620-2,700) ↓	Acinetobacter baumannii Carbapenems 478 UI (347-609) ↑
	Klebsiella pneumoniae 3GC 2,120 UI (1,580-2,660) ↓	Streptococcus pneumoniae Carbapenems 359 UI (203-515) ↓
	Acinetobacter baumannii Carbapenems 2,000 UI (1,480-2,530) ↑	Staphylococcus aureus Methicillin 339 UI (224-453) ↑
	Acinetobacter baumannii 4GC 2,000 UI (1,480-2,530) ↓	Pseudomonas aeruginosa Carbapenems 224 UI (127-320) ↑
	Acinetobacter baumannii Anti-pseudomonal 1,900 UI (1,410-2,400) ↓	Acinetobacter baumannii Fluoroquinolones 212 UI (160-263) ↓
	Streptococcus pneumoniae TMP-SMX 1,850 UI (1,100-2,610) ↓	Klebsiella pneumoniae 3GC 177 UI (102-253) ↓
	Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib. 1,800 UI (1,220-2,380) ↓	Klebsiella pneumoniae Carbapenems 125 UI (85-165) ↑
	Acinetobacter baumannii Fluoroquinolones 1,730 UI (1,260-2,210) ↓	Klebsiella pneumoniae Aminoglycosides 111 UI (71-152) ↓
	Klebsiella pneumoniae TMP-SMX 1,590 UI (1,130-2,050) ↓	Klebsiella pneumoniae Fluoroquinolones 111 UI (67-155) ↓
	Klebsiella pneumoniae Aminoglycosides 1,580 UI (1,110-2,050) ↓	Acinetobacter baumannii Aminoglycosides 101 UI (62-140) ↓

Annualized rate of change (1990-2021):
 <-3% (dark blue), -3% to -1.5% (medium blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (light orange), 3% to 5% (dark orange), >5.0% (red)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (12,900 UI (9,490-16,200)), lower respiratory infection (excl. COVID) (10,500 UI (7,790-13,200)), diarrhea (2,220 UI (101-4,330)), tuberculosis (1,330 UI (794-1,860)) and peritoneal and intra-abdominal infections (1,220 UI (767-1,670)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Sudan, people aged under 5 saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that under 5 continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the under 5 was 5,110 UI (3,490-6,740), whereas the mortality rate per 100,000 was 486 UI (367-604).

Data sources for Sudan

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Sudan by source type

Source type	Years	Sample size	Sample size units
Antibiotic use	2010-2021	6,473	Study-year datapoints
Microbial or laboratory data without outcome	1990-2021	309	Isolates
Literature studies	1990-2021	4,626	Cases/isolates/susceptibility tests
Single drug resistance profile data	2010-2021	3,598	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>